T. Rowe Price Investment Management, Inc. Apellis Pharmaceuticals, Inc. Transaction History
T. Rowe Price Investment Management, Inc.
- $158 Billion
- Q2 2024
A detailed history of T. Rowe Price Investment Management, Inc. transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, T. Rowe Price Investment Management, Inc. holds 4,048,412 shares of APLS stock, worth $115 Million. This represents 0.1% of its overall portfolio holdings.
Number of Shares
4,048,412
Previous 4,605,721
12.1%
Holding current value
$115 Million
Previous $271 Million
42.64%
% of portfolio
0.1%
Previous 0.17%
Shares
8 transactions
Others Institutions Holding APLS
# of Institutions
299Shares Held
113MCall Options Held
5.21MPut Options Held
691K-
Wellington Management Group LLP Boston, MA16.4MShares$467 Million0.11% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA11.6MShares$331 Million15.74% of portfolio
-
Avoro Capital Advisors LLC New York, NY11.1MShares$316 Million5.82% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.81MShares$279 Million0.01% of portfolio
-
Black Rock Inc. New York, NY5.8MShares$165 Million0.01% of portfolio
About Apellis Pharmaceuticals, Inc.
- Ticker APLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 109,865,000
- Market Cap $3.13B
- Description
- Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...